- New framework brings together 108 rare lysosomal disorders, substantially expanding the number included in traditional classifications
- Lysosomal disorders can have devastating effects on patients, including severe muscle weakness and progressive, potentially fatal damage to the nervous system
- Findings from the University of Sheffield-led collaborative study could support more precise diagnosis and help researchers identify shared targets for future treatments
Scientists have brought together the most comprehensive picture yet of rare metabolic disorders, identifying 108 conditions, almost double those originally understood to exist, bringing new hope for early diagnosis and innovative treatments.
People living with lysosomal disorders can endure a range of symptoms, such as kidney problems, severe muscle weaknes, progressive and fatal damage to the nervous system, depending on their diagnosis.
Lysosomes are specialised structures within cells that break down and recycle cellular material.
Traditionally, lysosomal disorders have largely been understood as conditions in which deficiencies of lysosomal enzymes or related proteins lead to the accumulation of "storage" material within cells.
However, advances in cell biology have revealed that lysosomes do much more than dispose of cellular waste.
They are involved in processes including cellular signalling, nutrient sensing, membrane trafficking, autophagy (the process by which cells recycle their own components) and communication between different structures within cells.
Established science only classed 70 conditions as lysosomal disorders.
But a pioneering study involving researchers at the University of Sheffield and across the country has now uncovered 108 disorders, including those not caused by enzyme deficiencies, for the first time.
Published in the Journal of Inherited Metabolic Disease (JIMD), the study presents a new classification encompassing inherited disorders in which disruption of these
wider lysosomal functions contribute significantly to disease.
After evaluating disorders against predefined criteria, the researchers classified 108 conditions caused by defects in 102 genes across 11 categories. The analysis also highlighted the complex and frequently multisystem nature of these disorders.
The findings show that the disease reaches far beyond a single area of the body. Roughly 80 per cent of patients experienced brain and nerve issues, and 68 per cent experienced eye complications. Digestive, bone, and blood-related issues were also common.
Dr Eamon McCarron, lead author of the study, Honorary Senior Lecturer at the University of Sheffield's School of Medicine and Population Health and Consultant and Clinical Lead in Adult Inherited Metabolic Disorders at the Sheffield Adult Metabolic Service, said: "Lysosomal disorders are individually rare, but their effects can be debilitating and, in some cases, life-limiting.
"Our understanding of the lysosome has changed enormously. We now know that it is not simply the cell's waste-disposal system, and lysosomal disease cannot always
be understood solely in terms of an enzyme deficiency and the accumulation of material within cells.
"By bringing together 108 inherited disorders within a framework based on modern lysosomal biology, we hope to provide a clearer way of understanding how these
diseases relate to one another.
"This could support more precise diagnosis and genetic interpretation and, in the longer term, help researchers identify shared disease mechanisms that could
become targets for new treatments. It may also help inform the future development of newborn screening strategies and clinical trials."
The researchers say grouping diseases according to shared biological mechanisms could help identify groups of patients who may benefit from therapies targeting
common disease pathways.
This could be particularly important for ultra-rare conditions, where conventional clinical trials evaluating treatments for individual disorders can be difficult.
The study was led by Dr Eamon McCarron at the University of Sheffield and Dr Karolina Stepien, Consultant in Adult Inherited Metabolic Diseases at Salford Royal
Hospital, and brought together expertise from institutions across the UK and internationally, including the University of Oxford, University College London and the
University of Manchester, alongside international experts from University Children's Hospital Zürich in Switzerland, Leiden University in the Netherlands, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the US National Institutes of Health.
